Atrial Fibrillation Risk Management and Emerging Therapies
Journal of Clinical Medicine · 14.06.2026 · 15 (12) · 4612
DOI: 10.3390/jcm15124612 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.06.2026. Verfasst von Megan Vaughan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, WV 26506, USA. Die Arbeit nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Atrial fibrillation (AF) is the most common tachyarrhythmia worldwide. Accompanying the increasing age of the general population, as well as an increase in underlying cardiovascular disease in the United States, is an explosive rise in the incidence and prevalence of this condition. We reviewed observational cohort studies, systematic reviews, meta-analyses, and randomized controlled trials (RCTs) to determine both underlying risk factors and treatment of AF, with particular focus on comorbid conditions influencing treatment success. Numerous studies have demonstrated a reciprocal relationship between maladaptive cardiac remodeling and AF, with the suggestion that aggressive management of both AF itself and resultant cardiovascular disease can lead to reversal of both conditions. Ultimately, many modifiable risk factors for AF exist, with treatment delays associated with a shift towards these conditions becoming unmodifiable. While a large area of focus for AF research has been on determining the optimal pharmacological strategy (i.e., rate versus rhythm control), results have been mixed, with emerging guidelines now pointing towards a flexible treatment strategy that allows for consideration of patient comorbid conditions, medication ease and affordability, and patient preference. Treatment of AF also includes prevention of thromboembolic events. In recent years, novel strategies for surgical or physical occlusion of the left atrial appendage (LAA) with devices such as the Watchman have arisen. Multiple large RCTs have demonstrated the safety and efficacy of these devices, but consideration must be given towards the patient’s bleeding risk, as short-term courses of blood thinners are still considered the standard of care. Finally, emerging therapies for AF include novel drug combinations, neuromodulation devices, and potentially glucagon-like peptide receptor-1 (GLP-1) agonist medications for reduction in overall metabolic disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, West Virginia University School of Medicine, Morgantown, WV 26506, USA.
- Department of Cardiovascular Medicine, West Virginia University School of Medicine, 1 Medical Center Dr, Box 8500, Morgantown, WV 26506, USA.
- Department of Cardiovascular Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, MI 48073, USA.
ORCID-Profile: Banveet Kaur
Zitieren
APA
Vaughan, M., Kaur, B., & Mehta, N. K. (2026). Atrial Fibrillation Risk Management and Emerging Therapies. Journal of Clinical Medicine, 15(12), 4612. https://doi.org/10.3390/jcm15124612
Vancouver
Vaughan M, Kaur B, Mehta NK. Atrial Fibrillation Risk Management and Emerging Therapies. Journal of Clinical Medicine. 2026;15(12):4612. doi:10.3390/jcm15124612
BibTeX
@article{Vaughan2026,
author = {Vaughan, Megan and Kaur, Banveet and Mehta, Nishaki K},
title = {Atrial Fibrillation Risk Management and Emerging Therapies},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {12},
pages = {4612},
doi = {10.3390/jcm15124612}
}
EUVIMED